Work

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.7000

Authors: R. Jotte, J. Von Pawel, D. R. Spigel, M. A. Socinski, M. O'Brien, E. H. Paschold, J. Mezger, M. Steins, L. Bosquée, J. A. Bubis, K. Nackaerts, J. M. Trigo Perez, P. R. Clingan, W. Schuette, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd, R. McNally, M. F. Renschler

Institutions: University of North Carolina at Chapel Hill, St. Vincentius-Kliniken, Royal Marsden Hospital, Tennessee Oncology

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2096542078

Cites:

Cited by: 49

Related to: 10